Results: 3

1.
Figure 3

Figure 3. Effect of Telmisartan on the Risk of Stroke or Major Cardiovascular Events in Prespecified Subgroups. From: Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events.

Shown are the effects telmisartan on the risks of stroke (Panel A) and major cardiovascular events (Panel B) in prespecified subgroups and in patients who underwent randomization either 10 days or less after the qualifying stroke or more than 10 days after the qualifying stroke. The sizes of the squares are proportional to the numbers of events. For details on calculation of the stroke risk score, see the Supplementary Appendix.

Salim Yusuf, et al. N Engl J Med. ;359(12):1225-1237.
2.
Figure 1

Figure 1. Kaplan-Meier Curves of the Cumulative Probability of Recurrent Stroke (Primary Outcome). From: Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events.

During a mean follow-up of 2.5 years, 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% CI, 0.86 to 1.04; P = 0.23). Hazard ratios were calculated with the use of the Cox model, which was adjusted for baseline age, use of angiotensin-converting-enzyme inhibitors, diabetes status, and modified Rankin Scale score.

Salim Yusuf, et al. N Engl J Med. ;359(12):1225-1237.
3.
Figure 2

Figure 2. Kaplan-Meier Curves of the Cumulative Probability of a Major Cardiovascular Event or New-Onset Diabetes (Secondary Outcome). From: Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events.

A composite of major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P = 0.11) (Panel A). Hazard ratios were calculated with the use of the Cox model, which was adjusted for baseline age, use of angiotensin-converting–enzyme inhibitors, diabetes status, and modified Rankin Scale score. New-onset diabetes occurred in 125 of 7306 patients patients (1.7%) in the telmisartan group and 151 of 7283 patients (2.1%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P = 0.10) (Panel B).

Salim Yusuf, et al. N Engl J Med. ;359(12):1225-1237.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk